Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05723055 · ClinicalTrials.gov registry record · Phase 2
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
A Phase 2 study of Hodgkin Lymphoma, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 2
- Study locations
NCT05723055 is a Phase 2 study of Hodgkin Lymphoma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 9 participants, below the 166-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05723055, a Phase 2 study of Hodgkin Lymphoma, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to study the combination of nivolumab and axatilimab in patients with relapsed/refractory classical Hodgkin Lymphoma. This study will mainly look at if the combination works as expected.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Axatilimab
Study Locations (2)
Michigan
- Karmanos Cancer Institute - Detroit
Utah
- Huntsman Cancer Institute at the University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-05-03 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05723055
The ClinicalTrials.gov registry entry for NCT05723055 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 166-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (95% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT05723055 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, Utah.
Frequently Asked Questions
What is clinical trial NCT05723055 about?
NCT05723055 is a clinical study titled "Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma". The goal of this clinical trial is to study the combination of nivolumab and axatilimab in patients with relapsed/refractory classical Hodgkin Lymphoma. This study will mainly look at if the combination works as expected.
What is the current status of trial NCT05723055?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2023-05-03. Estimated completion is 2028-04.
What conditions does trial NCT05723055 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT05723055?
The interventions under investigation include: Nivolumab (DRUG), Axatilimab (DRUG).
Who is sponsoring clinical trial NCT05723055?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05723055 being conducted?
This trial has 2 study locations across Michigan, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
RECRUITING · Phase 2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.